← Back to Search

Monoclonal Antibodies

Evaluation of ARI-3037MO, to Suppress LDL Cholesterol in Patients With Dyslipidemia (REASCEND Trial)

Phase 2
Waitlist Available
Research Sponsored by Arisaph Pharmaceuticals Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 wks

Summary

The objective of this study is to evaluate the efficacy and safety of ARI-3037MO compared to placebo in reducing low-density lipoprotein cholesterol (LDL-C) levels in subjects with dyslipidemia.

Eligible Conditions
  • High Cholesterol

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 wks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 wks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
LDL-c
Secondary study objectives
HDL-c
HbA1C
TG

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: ActiveActive Control1 Intervention
ARI-3037MO (niacin analog) 3g bid for 24 wks
Group II: PlaceboPlacebo Group1 Intervention
Matching Placebo 3g bid for 24 wks

Find a Location

Who is running the clinical trial?

Arisaph Pharmaceuticals IncLead Sponsor
2 Previous Clinical Trials
91 Total Patients Enrolled
~17 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top